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Abstract
Objectives: In memory clinics, patients with significant memory complaints without
objective neuropsychological findings are common. They are classified as subjective
cognitive decline (SCD) and, as a group, face a heightened risk for future dementia.
However, the SCD group is heterogeneous and comprises patients suffering from a
somatoform condition, namely functional cognitive disorder (FCD). These patients
make up at least 11% of memory clinics' attendees. The aim of this long‐term
follow‐up study was to investigate if patients diagnosed with FCD also face a higher
risk of developing dementia.
Methods: Forty‐two Patients were recruited at a university hospital memory clinic.
FCD was diagnosed according to the Schmidtke criteria (see Table 1). Ten years
later, all were invited again. Participants were interviewed, screened for depression
and given neuropsychological tests of verbal memory and information processing
speed. Cognitive impairment was defined as performance below 1.5 standard
deviations (SD) of the age‐related mean.
Results: Twenty‐eight of 42 patients (67%) took part in this follow‐up. The group's
mean results in both cognitive measures were stable over time. All individual perfor-
mances were within 1.5 SD. With 10 patients (24%), brief contact was successful and
manifest dementia could be excluded. Four patients (10%) could not be contacted.
Conclusions: In retrospect, the Schmidtke criteria for FCD safely identified memory
clinic attendees with SCD who did not proceed to Mild Cognitive Impairment or
dementia. None of the patients who could be contacted for this follow‐up after a
decade (90% of baseline participants) showed signs of dementia.
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1 | INTRODUCTION
1.1 | Subjective cognitive decline and functional
cognitive disorder
In memory clinics, patients suffering from significant memory com-
plaints butwithout objective findings in neuropsychological testing are
a frequent phenomenon.1 An international working group defined the
term subjective cognitive decline (SCD) for this syndrome.2
A systematic review investigated diagnoses given in memory clinics—
and foundmild cognitive impairment (MCI) or dementia in only 67% of
the cases. Twenty‐four percentage of the patients presenting with
cognitive symptomswere classified as SCDwithout objective cognitive
impairment, functional cognitive disorder (FCD) or pseudodementia.1
The challenge around the concept of SCD is the heterogeneous etiol-
ogy of cognitive symptoms among these patients and their unknown
future course. Some will proceed to develop dementia and others will
not. Current literature indicates that annual conversion rates among
elderly patients with SCD (mean age around 75 years) to dementia lie
around 2.3%, toMCI around 6.6%. Compared to controls without SCD,
this corresponds to a relative risk of 2.0.3,4 Rates differ depending on
setting (lower in community‐dwelling individuals vs. memory clinic
attendees) and age.5 For younger cohorts of memory clinic attendees
with SCD (aged 55–65), there is sparse literature concerning their risk
for future dementia. With age as the main risk factor for dementia,
there is a low risk in this group, but it is not “zero.” Large population
based studies found significant prevalence rates of amnestic MCI in
this age group of around 7%–10%.6,7 Thus, memory complaints even in
the “younger old” should be taken seriously, although the majority of
patients in this age group will not proceed to develop dementia.5,8–12
The issue is pertinent for patient selection for early intervention
studies aiming at disease modification in incipient dementia. To date,
there is no biomarker‐based diagnostic pathway to differentiate be-
tween degenerative, other organic and nonorganic etiologies at the
time of first appearance of SCD. Also, there are no established thera-
peutic measures.13 Recent research into SCD has focused on the
identification of patients at risk for dementia, but patients with non-
degenerative etiologies constitute the larger subset. The most com-
mon causes for their amnestic complaints are psychiatric and
psychological disorders like depression or FCD.1,14–17 Cognitive
complaints in depression are well‐described and part of the diagnostic
criteria of major depression.18,19 The etiology of subjective memory
impairment in the absence of organic disease hast been discussed in a
previous contribution of ours.20 Patients with FCD represent a rele-
vant proportion of memory clinic attendees. Prevalences differ
between institutions and countries from around 11%20,21 to distinctly
higher rates.22 Patients with FCD suffer substantially from memory‐
related lapses in their daily life, despite normal neuropsychological test
performances. Given the association of this disorder with relevant
stress burden and neuroticism, classification of FCD as a somatoform
disorder has been suggested.23,24 Patients with FCD are genuinely
concerned about their memory lapses and therefore—from a symp-
tomatological point of view—they mostly qualify for the high‐risk
subgroup of “SCDplus,” as defined by the SCD Initiative Working
Group.2 This classification is based on consistent concerns about
memory problems and linked to an increased risk to developMCI later
in life.25 Such facts can lead to a false attribution of neurodegenerative
etiology to genuinely functional memory symptoms. In a SCD group
who fulfilled FCD criteria, different from the group examined in the
present study, no increased incidence of dementia was detected17—
although these findings are limited through the relatively short follow‐
up interval of 20 months. The severity of self‐reported memory‐
related symptoms is not instrumental for the prediction of
dementia.26,27 Interactional profiles can help differentiate patients
with FCD from those suffering from a manifest neurodegenerative
disease as these groups show distinct patterns of communication in
neurological encounters.28,29 They might also be valuable for the
challenge of separating FCD from cases of prodromal dementia as
opposed to MCI or manifest dementia, but have not been validated
for this group. The Schmidtke criteria aim to identify patients
with functional cognitive symptoms and include a diagnostic tool
addressing the specific and characteristic complaints found in patients
with FCD.17
1.2 | Aims of the study
The aim of the present study was to test the hypothesis that patients
diagnosed with a nonorganic memory disorder do not develop
dementia over an extended period of time. To this end, we conducted
a 10 year follow‐up of the FCD cohort that took part in the study
published by Metternich et al.20 Comparable long‐term studies
investigating the risk of future dementia in patients with FCD have
not yet been carried out.
2 | MATERIALS AND METHODS
In 2005 and 2006, our group designed a pilot study investigating the
efficacy of a group therapy program for patients with FCD in a
randomized controlled trial. The same group was now reassessed.
Key points
� Patients with nonorganic functional cognitive disorders
are a frequent phenomenon in memory clinics
� Functional cognitive disorder (FCD) is an important dif-
ferential diagnosis in patients with Subjective cognitive
decline (SCD)
� Patients with functional cognitive Ddisorder are not at
heightened risk for future dementia—like it is known for
patients with SCD
� The Schmidtke criteria for FCD safely identify patients
who will not proceed to develop dementia
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2.1 | Subjects
Recruitment took place at the Centre for Geriatric Medicine and
Gerontologyof theUniversityHospital Freiburg,Germany, in2005and
2006. Patients were referrals from general practitioners, neurologists,
and psychiatrists. All patients presentingwithmemory symptomswere
screened for inclusion according to the criteria shown in Table 1.
All patients who had completed baseline measures (n ¼ 42) were
contacted again for this follow‐up in 2016 and invited to an appoint-
ment. Contact included a brief letterwith information on the follow‐up
study and a subsequent telephone call by the study physician. In case of
refusal to take part in an assessment, we applied the interactional
profiles published by Reuber and colleges to these telephone conver-
sations in order to analyze the probability of a potential neurodegen-
erative disease.28 For those who consented to take part, assessments
included medical and psychiatric history taking, neuropsychological
testing, FCD symptom evaluation and screening for depression.
2.2 | Measures
FCD was diagnosed using the funtional memory disorder (FMD)
Inventory, a structured interview designed and evaluated by
Schmidtke and Metternich.30 It contains 10 items assessing a range of
memory complaints found to be indicative of FCD.17 Each item/
symptom is rated as absent (0 P.), mildly present (0.5 P.), or present
(1 P.). The diagnostic cutoff is above 5 P.
All patients underwent neuropsychological testing of declarative
memoryusing theGermanversionof theAuditoryVerbalLearningTest
(VLMT),31 where 15words are presented orally over five trials and the
subjects are asked to repeat asmanyof thesewords as possible on each
trial, followed by a delayed free recall after 30 min. For our analysis of
performance in declarative memory, we used delayed free recall.
Information processing speed was assessed using the “Zahlenver-
bindungstest” (ZVT), a demanding paper‐and‐pencil digit connection
test with four trials, each requiring the test subject to connect the
numbers from1 to90.Objective cognitive impairmentwas defined as a
performance below 1.5 standard deviations (SD) of the age‐related
mean. At baseline, verbal intelligence was estimated using the
Mehrfachwahl‐Wortschatztest (MWT‐B, Lehrl, 2005), a widely used
German vocabulary test.
Depression was assessed using the Beck Depression Inventory
(BDI), where the cutoff score for clinically relevant depression is
defined as >17 points.32
2.3 | Analysis
Statistical analysis was performed using SPSS Version 23.0. For the
comparison of cognitive performance results on group level, we used
paired samples t‐test for both raw values and age‐adapted percentile
ranks (PR). Patients with clinically relevant depression were excluded
from this analysis (n ¼ 4). Individual results were controlled for the
definition of cognitive decline as mentioned above (within 1.5 SD).
Additionally, all individual results were examined for relevant change
over time in raw values and age‐adapted PR using the reliable change
criterion. These individual statistics were performed for all patients.
3 | RESULTS
3.1 | Patient flow
Of 42 patients of the original study, 28 (67%) consented to take part at
follow‐up. With another 10 (24%) patients contact was successful, but
they did not agree to participate. Four (10%) could not be contacted at
all, because their addresses were unknown. There were no significant
differences in main baseline demographic and memory related vari-
ables between participants and drop‐outs (see Table 2). The 28 par-
ticipantswere 64 years old on average at the time of follow‐up (SD¼7;
range ¼ 50–78 years). At follow‐up 42% of participants still fulfilled
diagnostic criteria for FCD as assessed in the FMD‐inventory. This
corresponds to a significant reduction (p ¼ 0.001).
Four out of the 28 participants were excluded from testing
because of a clinically relevant depression (BDI > 17 points). Two
participated in a telephone interview only. In one, ZVT testing was
TAB L E 1 Applied FCD criteria of the 2008 study21
Inclusion Exclusion
Performance in neuropsychological memory testing within
1.5 SD of age‐related mean
Dementia or MCI
Premorbid intelligence: Estimated IQ ≥ 80 History of early‐onset dementia in first‐grade relatives
FMD‐inventory with score > 5 points Psychiatric condition with clinical relevance at time of inclusiona
Clinical impression of probable FCD (e.g. relevant stress burden) Neurological condition with clinical relevance at time of inclusionb
Age ≤ 69 Medication with influence on memory performance
Abbreviations: FCD, functional cognitive disorder; FMD, funtional memory disorder; IQ, intelligence quotient; MCI, mild cognitive impairment.
aAttention deficit hyperactivity disorder (ADHS), post traumatic stress disorder (PTSD), substance‐related/addictive disorders, schizophrenia/other
psychotic disorder, major depression, bipolar disorder, generalized anxiety disorder, obsessive‐compulsive disorder.
bTraumatic brain injury, stroke, epilepsy, multiple sclerosis or other relevant neurological conditions in medical history that may affect cognitive
performance at time of inclusion.
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not applicable due to visual impairment. Thus, there were 21 cases
for ZVT and 24 for Auditory Verbal Learning Test (AVLT) testing.
3.2 | Cognitive performance
3.2.1 | Auditory Verbal Learning Test
There was no significant change in delayed recall of the AVLT over
time (see Table 3). In total, the results at follow‐up were above the
age‐related mean of 10.6 P (SD ¼ 2.9; reference group aged 60–69
years33). Furthermore, raw data at baseline and follow‐up were
transformed into age‐adapted PR. There was no significant change
over time in these measures (see Table 3). All individual results in
delayed recall of AVLT were within the range of 1.5 SD (age‐
adapted), defined as non‐impaired cognitive performance. When
comparing individual performances at baseline and follow‐up, there
was no case of significant change in delayedrecall of the AVLT
(according to the reliable change criterion). These results were not
altered significantly by the inclusion of the four cases with clinically
relevant depression measures.
3.2.2 | Cognitive speed (ZVT)
In cognitive speed testing, the mean age‐adapted percentile rank of
the group was stable over time (according to the reliable change
criterion). There was a significant decline in raw scores over time (see
Table 3). All individual results were within the normal range of 1.5 SD
(age‐adapted), including the four cases that showed a clinically
relevant depression. Among this group of patients excluded due to
depression, there was one case of significant change over time from
PR 95 to PR 66.
4 | DISCUSSION
Ourfindings show that SCDpatientswho fulfill FCDcriteria donot face
a heightened risk of future development of dementia or MCI within a
time period of 10 years. At follow‐up, all individual scores remained
within 1.5 SD of the age‐related means. Group results in cognitive
performance measures were stable and above age‐related means.
There are some limitations to this study that need to be
addressed. First, our cohort was rather young at baseline (mean age
55 years), thus their pretest risk for developing dementia was lower
than known for elder SCD cohorts.3–5 Population based prevalence
rates of amnestic MCI in this age group are around 7%–10%.6,7 But
evidence for conversion rates from SCD to MCI/dementia in younger
patients is sparse: Few studies focus on these “younger old” (55–65
years), most have small sample sizes and/or follow‐up intervals are
relatively short. Reisberg and colleagues showed that the follow‐up
interval needed to detect a later development of MCI/dementia in
patients with SCD is rather long.34 They evaluated MCI/dementia
after a mean time of 5.8 years (þ/  SD 3.1 years; mean age 68;
n ¼ 166). To our knowledge, there are two studies with a sufficient
follow‐up interval: Hessen and colleagues studied a cohort of 81
memory clinic patients with SCD for 6 years (mean age 61 years).
They found annual conversion rates to MCI and dementia of 1.5%
and 0.8%, respectively.8 Eckerström and colleagues followed a cohort
partly overlapping to but different from Hessen's cohort (mean age
TAB L E 2 Comparison of baseline
demographic variables of participants
and drop‐outs
Baseline Data (2006) Status at follow‐up (2016) N Mean SD Sig. p
Age Participants 28 54.7 6.8 0.80
Drop‐outs 14 55.5 10.4 ‐
Education Participants 28 15.2 3.8 0.31
Drop‐outs 14 14.2 2.8 ‐
MWTB Participants 28 31.9 3.2 0.95
Drop‐outs 14 32.0 3.5 ‐
VLMT (delayed recall) Participants 28 13.0 2.0 0.46
Drop‐outs 14 12.5 2.4 ‐
ZVT Participants 28 83.8 18.7 0.75
Drop‐outs 14 81.7 21.4 ‐
BDI Participants 28 7.6 4.9 0.85
Drop‐outs 14 7.9 3.8 ‐
FMD‐inventory Participants 28 7.1 1.0 0.80
Drop‐outs 14 7.2 1.2 ‐
Abbreviations: BDI, Beck Depression Inventory; FMD‐Inventory, Functional Memory Disorder
inventory; MWTB, “Mehrfach‐Wortschatz‐Intelligenztest B”; VLMT, German version of the AVLT
(auditory verbal learning test); ZVT, “Zahlenverbindungstest.”
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62 years; n ¼ 122). They found higher annual conversion rates of
6.8% to MCI and 2.1% to dementia.9 These rates are comparable to
those published for elderly SCD cohorts aged around 75 years.3
There are several studies with shorter follow‐up intervals (1.8–3.5
years).5,10–12 To sum up, annual conversion rates differ strongly
among studies: for dementia they vary from 0.6% to 2.1% per year,
for MCI from 1.5% to 6.8%.5,8–12 These rates would translate to 2–5
cases of dementia and 4–14 cases of MCI in our group of 28 SCD
patients after 10 years. The fact that we found no such cases at all
supports our hypothesis: the Schmidtke criteria safely identified
patients with FCD and long‐term cognitive stability Functional
cognitive symptoms can arise across the whole life span1 and
generalizability of our results to older FCD cohorts is not yet clear.
Further research is needed to study long‐term cognitive outcome in
larger FCD cohorts that include more individuals of older age at
baseline.
Second, the relatively small group of 42 patients is a limitation of
our study and selection bias may have been a problem. Out of the 42
participants at baseline, 28 (67%) underwent neuropsychological
testing for cognitive impairment at follow‐up. To minimize the risk of
missing cases with dementia in the remaining 14 (33%), we made an
effort to contact these individuals. Ten (24%) patients could be
contacted, but they did not agree to participate in the follow‐up
assessment. In all of these 10 cases, narratives indicated an absence of
impairment in activities of daily living, whichmakesmanifest dementia
very unlikely: Patients explained, for example, they had no time to
participate because they were busy traveling, caring for a demented
partner or working. Also, the character of communication (e.g., long
letter to the study physician, eloquent telephone conversationwith the
study physician) made an ongoing neurodegenerative process over ten
years very unlikely. We applied interactional profiles for differential
diagnosis of memory complaints as published by Reuber and
colleagues28 to the telephone protocols. In all cases assessed,we found
characteristics typical for FCD. Of course, MCI cannot be safely
excluded without neuropsychological testing. Yet, if the initial symp-
toms had been due to a preprodromal state of dementia, it is very
probable this condition would have worsened significantly over the
time span of a decade and reached a clinically manifest level34 To sum
up, 38 of 42 patients could be contacted in a way that makes manifest
dementia highly unlikely. In contrast, the age‐related conversion rates
for SCD patients as mentioned above would translate to 2–7 cases of
dementia in a group of 38 SCD patients after 10 years. We found no
such caseamong the38contactedpatients,makinga relevant selection
bias unlikely. Only four (10%) out of the 42 original patients could not
be contacted at all, because their addresses were unknown. Dementia
often forces people to leave their homes and seek care in a safer
setting. Thus, cases of dementia among thosewhomwecould not reach
are one possible explanation. Baseline data were not notably or
significantly different in patients and drop‐outs, supporting a nonse-
lective response to our follow‐up.
Another limitation of this study revolves around the lack of gold
standard diagnostic criteria for FCDagreed upon. The definition of this
entity is a topic of ongoing discussion. The criteria applied in this study
identify a rather “pure” group of FCD patients as they exclude in-
dividuals with any objective cognitive deficit or major neurological or
psychiatric condition. Several authors suggested a wider definition of
FCD, taking into account that functional cognitive symptoms occur
frequently in patients with neurological or psychiatric disorders.35
Thus, the results presented here may not be generalizable to FCD
populations with preexisting neurological or psychiatric conditions
and a “functional overlay.” Furthermore, we excluded all individuals
showing cognitive deficits (i.e., below 1.5 SD in neuropsychological
tests performed). Along with the above mentioned wider definition of
FCD, patients with nonspecific cognitive impairment may be included
into the FCD group.1 There are patients with MCI—due to neurolog-
ical, toxic or other causes—showing cognitive symptoms inconsistent
with their neuropsychological profile that are better explained by a
functional genesis, especially when considering a broader picture of
psychological factors and individual medical history.35 Of course, dif-
ferential diagnosis regarding early stages of neurodegenerative dis-
eases in these cases is a challenge. In contrast, our group of FCD
patients showed normal cognitive performance indicating the absence
of structural neurological damage. Our aimwas to study the long‐term
outcome of this specific but relevant subgroup with FCD. These pa-
tients represent a considerable percentage ofmemory clinic attendees
(i.e., around 11%, see introduction) with a potentially better cognitive
prognosis than other subgroups of FCD patients. Correspondingly,
Bessi and colleagues studied a large SCD population over 6 years and
found that strong performance in neuropsychological testing was
associated with low risk for future cognitive decline36 Another
TAB L E 3 T‐test for results in neuropsychological measures (raw scores and percentile ranks)
Mean Age (years)
AVLT (n ¼ 24) ZVT (n ¼ 21)
Mean (SD) Sig. P two‐sided Mean (SD) Sig. P two‐sided
Raw scores Baseline 55 13.2 (1.9) 0.90 81.5 s (17.8) 0.04
Follow‐up 64 13.1 (2.2) 88.4 s (25.6)
Percentile ranks Baseline 55 78a (24) 0.23 83.7a (14.4) 0.78
Follow‐up 64 83b (22) 84.4b (15.5)
Abbreviations: AVLT, Auditory Verbal Learning Test; ZVT, Zahlenverbindungstest.
aaccording to age norm 51–60 years.
baccording to age norm 61–70 years.
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limitation of the group studied here is that our neuropsychological test
protocol was confined to declarativememory and cognitive processing
speed. There may be patterns in FCD concerning other cognitive do-
mains we did not include or test for like symptoms regarding selective
attention, verbal fluency and so on.
Another potentially confounding influence on cognitive symp-
toms that warrants consideration is depression. Major depressive
disorder can lead to subjective memory symptoms and objective
cognitive impairment and therefore was an exclusion criterion for our
definition of FCD Our cohort showed slightly elevated depression
scores at baseline compared to healthy controls. It did not differ in
other measures linked to depression like rumination and automatic
negative thoughts (see other publications on this cohort by Metter-
nich and colleagues20,23,37). Affective symptoms are common in
patients with MCI and dementia as well. Elfgren and colleagues
compared psychiatric symptoms in patients with SCD to those with
MCI/dementia—after having excluded all patients diagnosed with a
major psychiatric disorder like depression. They found no significant
differences between these groups concerning depressed mood.10
Overall, this follow‐up study did not find any indications that
patients presenting with SCD and an additional diagnosis of FCD face
an increased risk for future MCI or dementia. In the last decade,
increased scientific and clinical effort have been directed at the early
diagnosis of preclinical stages of dementia among patients with
SCD.1,38,39 Patients suffering from the somatoform disorder FCD
may be wrongly assigned to a group facing an elevated risk of future
dementia—an issue also highlighted by Mc Whirter and colleagues in
their systematic review addressing FCDs.1 Patients with FCD often
fear their memory lapses are due to a neurodegenerative process.
Such a false assignment to a high‐risk group may aggravate their
symptoms and worsen the situation. Thus, it is relevant to differen-
tiate safely between FCD and dementia‐risk‐patients among those
presenting with SCD.
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